FDA-cleared profile

AVIEW Lung Nodule CAD

Coreline Soft Co.,Ltd · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.

Clinical role
Adjunctive alert and second reader after the radiologist's first read.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: The software is an adjunct, not a replacement for radiologist interpretation. The cleared population is asymptomatic, the input is non-contrast chest CT, and the FDA summary recommends limiting use to Siemens SOMATOM series.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: Non-contrast chest CT for asymptomatic populations; FDA recommends limiting use to Siemens SOMATOM series because the validation data were predominantly from that scanner family.
  • Who uses it?Intended users: Radiologists and other qualified healthcare professionals interpreting chest CT.
  • What does the software produce?Output: Detected pulmonary nodules with marked regions of interest and quantified nodule values for radiologist review.
  • What is its most important limitation?Key limitation: The software is an adjunct, not a replacement for radiologist interpretation. The cleared population is asymptomatic, the input is non-contrast chest CT, and the FDA summary recommends limiting use to Siemens SOMATOM series.

Clinical takeaway. Clinical role: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.

Evidence takeaway. Evidence from the reviewed source record: The FDA summary describes nonclinical/software validation for nodule detection and analysis and states that no clinical study was considered necessary for this submission.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Adjunctive alert and second reader after the radiologist's first read.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Non-contrast chest CT for asymptomatic populations; FDA recommends limiting use to Siemens SOMATOM series because the validation data were predominantly from that scanner family.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Detected pulmonary nodules with marked regions of interest and quantified nodule values for radiologist review.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Healthcare imaging services using non-contrast chest CT.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists and other qualified healthcare professionals interpreting chest CT.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The software is an adjunct, not a replacement for radiologist interpretation. The cleared population is asymptomatic, the input is non-contrast chest CT, and the FDA summary recommends limiting use to Siemens SOMATOM series.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The FDA summary describes nonclinical/software validation for nodule detection and analysis and states that no clinical study was considered necessary for this submission.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA summary describes nonclinical/software validation for nodule detection and analysis and states that no clinical study was considered necessary for this submission.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

No single exact-submission clinical sensitivity endpoint was established in the reviewed FDA summary.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

No single exact-submission clinical specificity endpoint was established in the reviewed FDA summary.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

AVIEW Lung Nodule CAD K251203 validation

  • DesignNonclinical and software validation described in the FDA 510(k) summary
  • PopulationNon-contrast chest CT studies with pulmonary nodules in the cleared 3-20 mm range, predominantly acquired on Siemens SOMATOM scanners
  • Scopeexact submission
  • Tested versionAVIEW Lung Nodule CAD 2.0
  • IndependenceSponsor or vendor study

K251203

The public summary does not establish a clinical-outcome study or one consolidated sensitivity/specificity result.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

Reimbursement
Medicare National Coverage Determination 210.14 (version effective 2022-02-10) covers annual lung cancer screening with low dose CT under Part B as a preventive service for eligible beneficiaries (age 50-77, asymptomatic, at least 20 pack-years, current smoker or quit within 15 years, with an order and a prior counseling and shared decision-making visit). It requires a board-certified or board-eligible reading radiologist and a facility that uses a standardized lung nodule identification, classification and reporting system. The NCD does not mention AI or nodule-detection software. This is national service-level context, not a determination that this exact product is covered or separately paid. No payment amount or software-specific code was reviewed.
  • Service-level, not product-specific
  • Checked 2026-10-25

No product-specific code

National coverage of the LDCT lung screening service (NCD 210.14); software-specific coverage and payment not established

Medicare (Original Medicare, CMS) · United States · Effective 2022-02-10

The NCD covers the screening service and does not address AI software. It does not prove eligibility, coverage or separate payment for this product, version, patient, site or claim.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Non-contrast chest CT for asymptomatic populations; FDA recommends limiting use to Siemens SOMATOM series because the validation data were predominantly from that scanner family.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K251203: AVIEW Lung Nodule CAD

  2. Routing

    Source context, not route validation: Processes the CT study and presents nodule findings as radiologist-review information in the imaging workflow; exact local routing and PACS configuration require site confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K251203: AVIEW Lung Nodule CAD

  3. AI processing

    Source context, not route validation: Standalone software configuration described in the submission; the exact hosting and local service topology are not specified in the public summary.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K251203: AVIEW Lung Nodule CAD

  4. Returned objects

    Source context, not route validation: Detected pulmonary nodules with marked regions of interest and quantified nodule values for radiologist review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K251203: AVIEW Lung Nodule CAD

  5. Viewer/worklist/report

    Unresolved route: Detected pulmonary nodules with marked regions of interest and quantified nodule values for radiologist review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K251203: AVIEW Lung Nodule CAD

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Standalone software configuration described in the submission; the exact hosting and local service topology are not specified in the public summary.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
Processes the CT study and presents nodule findings as radiologist-review information in the imaging workflow; exact local routing and PACS configuration require site confirmation.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Coreline Soft states that AVIEW Lung Nodule CAD received US FDA 510(k) clearance renewal after meeting the FDA's strengthened cybersecurity review criteria, including security lifecycle management, Software Bill of Materials (SBOM) submission, encryption and access control, and vulnerability response systems.
  • Product family
  • Checked 2026-10-26

Vendor statement, not an attestation. Scope is the AVIEW Lung Nodule CAD product family as named in Coreline Soft's own news release; not extended to other AVIEW products.

Nodule detection and quantification

The cleared output marks detected nodules and provides ROI and quantified nodule values for radiologist review.

exact submission · checked 2026-09-07

Family chest CT workflow

Coreline presents AVIEW LCS as a chest CT nodule detection and analysis solution with report-oriented output.

product family · checked 2026-09-06

The family page does not establish local PACS routing, hosting, service levels or current availability for K251203.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251203
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-12-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
20Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, stored candidate metadata, literature index, trial registry, payer policy, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for the K251203 configuration was reviewed.

  • Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission

    License, per-study, subscription and implementation terms were not established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K251203: AVIEW Lung Nodule CAD

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AVIEW Lung Nodule CAD model card (K251203)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AVIEW LCS | AI for Nodule Detection & Analysis

    Coreline Soft Co., Ltd - Accessed 2026-09-06

    Scope: productFamilyContext, clinicalUse, output, implementationCapabilities

  8. CMS National Coverage Determination 210.14: Lung Cancer Screening with Low Dose Computed Tomography (LDCT)

    Centers for Medicare & Medicaid Services (Medicare Coverage Database) - Accessed 2026-10-25

    Scope: reimbursement, coverage, payerPolicy

  9. Coreline Soft Secures US FDA Clearance Renewal for AI Lung Nodule CAD

    Coreline Soft - Published 2025-12-08 - Accessed 2026-10-26

    Scope: security

Research history

  1. K251203 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K250766

LungQ 4

Thirona BV

Authorized purpose: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2025-10-02
FDA-cleared K242919

V5med Lung AI

V5med Inc.

Authorized purpose: V5med Lung AI provides concurrent-read adjunctive notification of suspected pulmonary nodules on chest CT; it does not replace radiologist judgment, diagnostic processes, or review of original CT series.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2025-03-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history